One Backbone, Multiple Viral Assets
AI-Driven Platform for Rapid Antiviral Drug Development
VIRITIS AT A GLANCE
- AI-driven antiviral drug discovery platform
- Proprietary antisense molecular technology
- 97.1% cellular protection in proof-of-concept studies
- Rapid development of targeted antiviral candidates
- Designed to address emerging viral threats
THE PROBLEM
Emerging viruses are evolving faster than drug development
Development of antiviral therapeutics traditionally takes many years. Meanwhile, new viral pathogens can emerge and spread globally within months.
Major challenges in antiviral drug development include:
• Long discovery and development timelines
• Viral mutation and resistance
• Limited ability to rapidly respond to new pathogens
• Complex manufacturing and distribution requirements
The COVID-19 pandemic demonstrated the urgent need for rapid and adaptable antiviral therapeutic platforms.
THE SOLUTION: EXHAUVIR
From Sequence to treatment
Finding conserved genomic sequence in the targeted virus
Customizing our molecule (EXHAUVIR)
EXHUAVIR enter the cells then attached to the target virus
Cellular mechanisms destroy the virus
EXHUVIR is completely disintegrated without harmfull residue
PROOF OF CONCPEST
Preliminary studies demonstrate strong antiviral activity of Viritis molecular design
Key findings include:
• 97.1% cellular protection in initial cellular assays
• Targeting of conserved viral sequences
• Efficient disruption of viral replication
These results support Viritis platform potential for rapid therapeutic generation.
MARKET OPPORTUNITY
A growing global antiviral therapeutics market
The global antiviral therapeutics market represents a multi-billion-dollar opportunity
- Increasing emergence of viral diseases
- Global pandemic preparedness programs
- Rising viral resistance to existing treatments
- Increased investment in antiviral drug development
Platform-based antiviral technologies have the potential to play a key role in addressing future global health challenges.